• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    MAIA Biotechnology, Inc. Common Stock (NY:MAIA)

    1.260 +0.020 (+1.61%)
    Streaming Delayed Price Updated: 10:46 AM EDT, Apr 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about MAIA Biotechnology, Inc. Common Stock

    < Previous 1 2 3 4 5 6 7 Next >
    What's going on in today's session ↗
    Via Chartmill
    These stocks are moving in today's session ↗
    Via Chartmill
    Which stocks are gapping on Tuesday? ↗
    Via Chartmill
    Which stocks are moving before the opening bell on Tuesday? ↗
    Via Chartmill
    News headline image
    Which stocks are gapping on Monday? ↗
    Let's have a look at the gap up and gap down stocks in today's session. 
    Via Chartmill
    News headline image
    Biotech Giant MAIA Biotechnology (NYSE American: MAIA) Dives Headfirst into Crypto with Audacious Treasury Strategy
    October 7, 2025 – In a move that sent ripples across both the biotechnology and cryptocurrency sectors, MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company... 
    Via BreakingCrypto
    Topics ETFs Economy
    News headline image
    Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
    EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:LPTX),(NASDAQ:IOBT),(NASDAQ:CELC),(NYSE:MAIA) EQNX::TICKER_END 
    Via FinancialNewsMedia
    News headline image
    12 Health Care Stocks Moving In Thursday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    MAIA Biotechnology Receives FDA’s Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer
    From MAIA Biotechnology, Inc.
    Via Business Wire
    News headline image
    MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy
    From MAIA Biotechnology, Inc.
    Via Business Wire
    News headline image
    MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer
    From MAIA Biotechnology, Inc.
    Via Business Wire
    News headline image
    MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress
    From MAIA Biotechnology, Inc.
    Via Business Wire
    News headline image
    MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board
    From MAIA Biotechnology, Inc.
    Via Business Wire
    News headline image
    MAIA’s New Agreement With Big Pharma Roche Turns Retail Investors Bullish As Stock Soars ↗
    The agreement aims to support future studies investigating the combination of MAIA’s Ateganosine and Roche’s checkpoint inhibitor, Atezolizumab, for safe and effective cancer treatments. 
    Via Stocktwits
    News headline image
    MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies
    From MAIA Biotechnology, Inc.
    Via Business Wire
    News headline image
    MAIA Biotechnology to Present at BIO International Convention 2025
    From MAIA Biotechnology, Inc.
    Via Business Wire
    News headline image
    MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients ↗
    MAIA posts 17.8-month median survival in NSCLC trial, nearly tripling standard care; long-term response seen in a chemo- and immunotherapy-resistant group. 
    Via Benzinga
    News headline image
    MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial
    From MAIA Biotechnology
    Via Business Wire
    News headline image
    MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer
    From MAIA Biotechnology, Inc.
    Via Business Wire
    News headline image
    CORRECTING and REPLACING MAIA Biotechnology Announces Private Placement of Approximately $695,000
    From MAIA Biotechnology, Inc.
    Via Business Wire
    News headline image
    MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
    From MAIA Biotechnology, Inc.
    Via Business Wire
    News headline image
    MAIA Biotechnology Announces Director Participation in Recent Private Placement
    From MAIA Biotechnology, Inc.
    Via Business Wire
    News headline image
    CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement
    From MAIA Biotechnology, Inc.
    Via Business Wire
    News headline image
    MAIA Biotechnology Announces $1.08 Million Private Placement
    From MAIA Biotechnology, Inc.
    Via Business Wire
    News headline image
    MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders
    From MAIA Biotechnology, Inc.
    Via Business Wire
    News headline image
    MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025
    From MAIA Biotechnology, Inc.
    Via Business Wire
    News headline image
    MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug
    From MAIA Biotechnology, Inc.
    Via Business Wire
    News headline image
    MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO
    From MAIA Biotechnology, Inc.
    Via Business Wire
    News headline image
    MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients
    From MAIA Biotechnology, Inc.
    Via Business Wire
    News headline image
    MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer
    From MAIA Biotechnology, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.